Reprogramming the solid tumor microenvironment
to unlock the full potential of cancer immunotherapy
This is Lever Bio
Our Vision
Our vision is to unlock biotech innovation in immuno-oncology working with researchers, universities and research centers to ultimately improve patient outcomes.
Our Approach
We focus on reprogramming the solid tumor microenvironment to foster anti-cancer immune response enhancing the recruitment, activation and sustained function of cytotoxic T lymphocytes against solid tumors.
Our compounds aim to be solid tumor microenvironment reprogramming agents and T-cell fitness potentiators
Join Lever Bio in advancing promising research and driving innovative drug development in the immuno-oncology field
Claris Ventures and Exor Ventures are joining forces in a new initiative, called Lever Bio, aimed at developing innovative drugs in collaboration with Italian universities and research centers.